| Issue | Title | |
| Vol 11, No 4 (2015): July/August | 12-Month safety and effectiveness of once-daily hydrocodone | Abstract |
| Warren Wen, PhD, Louise Taber, MD, Shau Yu Lynch, PhD, Ellie He, PhD, Steven Ripa, MD | ||
| Vol 10, No 4 (2014): July/August | 2014 INTERNATIONAL CONFERENCE ON OPIOIDS Posters presented June 8-10, 2014 | Abstract |
| JOM Editors | ||
| Vol 12, No 6 (2016): November/December | 2017 International Conference on Opioids Announcement | Abstract |
| 2017 ICOO Conference Committee | ||
| Vol 13, No 1 (2017): January/February | 2017 International Conference on Opioids Brochure and Schedule | Details |
| Conference Committee | ||
| Vol 15, No 5 (2019): September/October | 2019 International Conference on Opioids Photos | Abstract |
| International Conference on Opioids | ||
| Vol 15, No 5 (2019): September/October | 2019 International Conference on Opioids Posters | Abstract |
| International Conference on Opioids | ||
| Vol 12, No 6 (2016): November/December | A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation | Abstract |
| Lynn Webster, MD, Raj Tummala, MD, MBA, MS, Ulysses Diva, PhD, Jaakko Lappalainen, MD, PhD | ||
| Vol 14, No 3 (2018): May/June | A case for opioid education and training for medical students, residents, and allied health staff: response to “educational intervention for physicians to address the risk of opioid abuse” | Abstract |
| Anees Bahji, BScH, MD, Daenis Camiré, BScN, RN, MD | ||
| Vol 17, No 7 (2021): Special Issue - “Buprenorphine: Clinical and Public Policy Implications" | A case report of satisfactory post-left knee replacement pain control after switching from oxycodone to buprenorphine | Abstract |
| Shuo Qiu, MD, Sachinder Vasudeva, MD | ||
| Vol 15, No 3 (2019): May/June | A case report of sweating caused by hydromorphone | Abstract |
| Lauren E. Bode, PharmD, BCPS | ||
| Vol 10, No 3 (2014): May/June | A chart review based comparative study of retention rates for two dispensing regimens for buprenorphine for subjects with opioid dependence at a tertiary care substance use disorder treatment center | Abstract |
| Yatan Pal Singh Balhara, MD, DNB, MNAMS | ||
| Vol 14, No 6 (2018): November/December | A claims analysis of the utilization of tramadol for acute pain in patients prescribed buprenorphine/naloxone for opioid use disorder | Abstract |
| Kellye Donovan, PharmD, PhD, MHA, Stephen Kogut, PhD, MBA, Ashley Buchanan, DrPH, MS, Xuerong Wen, PhD, MPH, Robert Crausman, MD, MMS | ||
| Vol 8, No 2 (2012): March/April | A comparative study on the effects of intrathecal morphine added to levobupivacaine for spinal anesthesia | Abstract |
| Hakki Unlugenc, MD, Murat Gunduz, MD, Baris Guzel, MD, Geylan Isik, MD | ||
| Vol 7, No 5 (2011): September/October | A comparison of methods of administering the Opioid Risk Tool | Abstract |
| Ted Jones, PhD, Steven D. Passik, PhD | ||
| Vol 1, No 5 (2005): November/December | A comparison of oral and implant naltrexone outcomes at 12 months | Abstract PDF |
| Ross Colquhoun, BPsych(Hons), Donald Y-K. Tan, MBBS, Samantha Hull, BPsych(Hons) | ||
| Vol 3, No 2 (2007): March/April | A comparison of oral midazolam, oral tramadol, and intranasal sufentanil premedication in pediatric patients | Abstract PDF |
| Fatma Bayrak, MD, Isil Gunday, MD, Dilek Memis, MD, Alparslan Turan, MD | ||
| Vol 2, No 2 (2006): March/April | A comparison of patient-controlled epidural pethidine vs. nurse-administered epidural pethidine for analgesia after caesarean section | Abstract PDF |
| Yvonne Lim, MMed, Sally Wilson, Steven Katz, MD | ||
| Vol 1, No 1 (2005): March/April | A comparison of rapid (opioid) detoxification with clonidine-assisted detoxification for heroin-dependent persons | Abstract PDF |
| Diane E. Arnold-Reed, PhD, Gary K. Hulse, PhD | ||
| Vol 13, No 2 (2017): March/April | A comprehensive clinical review of opioid-induced allodynia: Discussion of the current evidence and clinical implications | Abstract |
| Corey J. Hayes, PharmD, MPH, Jacob T. Painter, PharmD, MBA, PhD | ||
| Vol 16, No 1 (2020): January/February | A departmental policy can reduce opioid prescribing after orthopedic surgery | Abstract |
| Simon C. Mears, MD, PhD, Asa Shnaekel, MD, MPH, John Wilkinson, MD, Caroline Chen, BS, C. Lowry Barnes, MD | ||
| Vol 2, No 2 (2006): March/April | A descriptive case series: Oral transmucosal fentanyl use in patients with noncancerous pain | Abstract PDF |
| Anthony H. Guarino, MD, Jennifer Myers, RN, MSN, ANP, Martha E. Cornell, RN, BSN | ||
| Vol 15, No 5 (2019): September/October | A double blind randomized clinical trial of buprenorphine augmentation for treatment of psychotic symptoms in opioid addicted bipolar patients | Abstract |
| Navid Khalili, MD, Abdolreza Sabahi, MD, Mostafa Vahedian, PhD, Mehdi Alimardanzadeh, MD | ||
| Vol 7, No 1 (2011): January/February | A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts | Abstract |
| Kushal Jain, MD, Raka Jain, PhD, FRSC Chem, Anju Dhawan, MD | ||
| Vol 6, No 5 (2010): September/October | A double-blind, placebo-controlled study of dual-opioid treatment with the combination of morphine plus oxycodone in patients with acute postoperative pain | Abstract |
| Lynn Webster, MD, Patricia Richards, MD, PhD, Warren Stern, PhD, Robin Kelen, RN, BA, CNN | ||
| Vol 17, No 7 (2021): Special Issue - “Buprenorphine: Clinical and Public Policy Implications" | A history of opioid abuse: Why buprenorphine is superior for the management of opioid use disorder and pain | Abstract |
| Michael D. Komrowski, MS, Nitin K. Sekhri, MD | ||
| Vol 15, No 3 (2019): May/June | A longitudinal analysis of temporal and spatial incidence of neonatal abstinence syndrome in Ontario: 2003-2016 | Abstract |
| Emily Dawson, MPH, Julia Lew, MD Candidate, Dane Mauer-Vakil, BKin, Adam Van Dijk, MSc, Paul Belanger, PhD, Kieran M. Moore, MD | ||
| Vol 16, No 1 (2020): January/February | A model for an institutional response to the opioid crisis | Abstract |
| Marie N. Hanna, MD, MEHP, Chester Chambers, PhD, Ananth Punyala, MS, Asniya Iqbal, MS, Bhuchitra Singh, MD, MPH, MS, Cagla Oruc, MS, Priyamvadha Prakash, MS, Yash Prajapati, MS, Yidong Wang, MS, Zeyu Amery Ai, MS, Ronen Shechter, MD, Traci J. Speed, MD, PhD, Colleen G. Koch, MD, MS, MBA, Kayode Williams, MD, MBA | ||
| Vol 12, No 6 (2016): November/December | A more balanced approach to opioid use and management is also needed in end-of-life care | Abstract |
| Sydney Morss Dy, MD, MSc, Cynda Hylton Rushton, PhD, RN, FAAN | ||
| Vol 10, No 6 (2014): November/December | A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain | Abstract |
| Samir Arora, MD, Beatrice Setnik, PhD, Michael Drass, MD, John D. Hudson, MD, Ray Clemmer, MS, Paul Meisner, PharmD, Glenn C. Pixton, MS, Veeraindar Goli, MD, Kenneth W. Sommerville, MD | ||
| Vol 15, No 6 (2019): November/December | A multicomponent intervention to improve adherence to opioid prescribing and monitoring guidelines in primary care | Abstract |
| Kristin T. L. Huang, MD, Deborah Blazey-Martin, MD, MPH, Daniel Chandler, MD, Alysse Wurcel, MD, MS, Joseph Gillis, BA, Julie Tishler, MD | ||
| Vol 16, No 4 (2020): July/August | A multidimensional Rasch analysis of the screener and opioid assessment for patients with pain-revised | Abstract |
| Courtney Morris, PhD, Kathy E. Green, PhD, Richa Ghevarghese, PhC | ||
| Vol 10, No 5 (2014): September/October | A multifactorial intervention for hospital opioid management | Abstract |
| Mehmet Akce, MD, Anupam Suneja, MD, Cheryl Genord, RPh, Bonita Singal, MD, PhD, John A. Hopper, MD | ||
| Vol 14, No 6 (2018): November/December | A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation | Abstract |
| Nadav Friedmann, PhD, MD, Michael R. Marsman, PharmD, Annelies W. de Kater, PhD, Lindsay H. Burns, PhD, Lynn R. Webster, MD | ||
| Vol 3, No 4 (2007): July/August | A new type of harm reduction: Creating an arteriovenous fistula for a compulsively injecting opiate user | Abstract |
| Colin Brewer, MB, Mohammed Sobeh, FRCS | ||
| Vol 4, No 5 (2008): September/October | A PARADOXICAL, NOVEL APPROACH: COMBINING MINUTE NALOXONE WITH MORPHINE INTRATHECAL INFUSION | Abstract |
| Xiulu Ruan, MD | ||
| Vol 2, No 6 (2006): November/December | A patient-activated iontophoretic transdermal system for acute pain management with fentanyl hydrochloride: Overview and applications | Abstract PDF |
| Kevin T. Bain, PharmD, BCPS, CGP, FASCP | ||
| Vol 11, No 5 (2015): September/October | A pharmacokinetic evaluation of single and multiple doses of extended-release hydrocodone bitartrate in subjects experiencing surgical or osteoarthritic pain | Abstract |
| Cynthia Y. Robinson, PhD, Christopher M. Rubino, PharmD, Stephen J. Farr, PhD | ||
| Vol 12, No 1 (2016): January/February | A phase I study of d-methadone in patients with chronic pain | Abstract |
| Natalie Moryl, MD, Cristina Tamasdan, MD, Dana Tarcatu, MD, Howard T. Thaler, PhD, Denise Correa, PhD, Richard Steingart, MD, FACC, Richard Payne, MD, Eugenie Obbens, MD, PhD | ||
| Vol 2, No 3 (2006): May/June | A Phase II, multicenter, randomized, double-blind, placebo-controlled crossover study of CJC-1008—a long-acting, parenteral opioid analgesic—in the treatment of postherpetic neuralgia | Abstract PDF |
| Mark S. Wallace, MD, Dwight Moulin, MD, A. J. M. Clark, FRCPC, Ronald Wasserman, MD, Ann Neale, Patricia Morley-Forster, MD, Jean-Paul Castaigne, MD, Sam Teichman, MD | ||
| Vol 1, No 2 (2005): May/June | A Physician’s Guide to Pain and Symptom Management in Cancer Patients. | Abstract PDF |
| Allen W. Burton, MD | ||
| Vol 5, No 6 (2009): November/December | A pilot study about the feasibility and cost-effectiveness of electronic compliance monitoring in substitution treatment with buprenorphine—naloxone combination | Abstract |
| Ulrich Tacke, MD, PhD, Hanna Uosukainen, MSci (Pharm), Marjo Kananen, BSci (Pharm), Kirsi Kontra, Pharm Lic, Hannu Pentikäinen, MD | ||
| Vol 10, No 1 (2014): January/February | A pilot study of nasal fentanyl for patient controlled treatment of cancer pain | Abstract |
| M. Thronæs, MD, S. Kaasa, MD, PhD, O. Dale, MD, PhD | ||
| Vol 4, No 2 (2008): March/April | A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners | Abstract |
| Sandra A. Springer, MD, Robert D. Bruce, MD | ||
| Vol 9, No 5 (2013): September/October | A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain | Abstract |
| Mila Etropolski, MD, Bernd Lange, MD, MSc, Jutta Goldberg, PhD, Achim Steup, Dipl.-Stat., Christine Rauschkolb, MD, PhD | ||
| Vol 11, No 1 (2015): January/February | A primer on definitive gas and liquid chromatography drug testing: What clinicians need to know | Abstract |
| Amadeo Pesce, PhD, Kenneth L. Kirsh, PhD, Angela Huskey, PharmD, CPE, Steven D. Passik, PhD, Catherine A. Hammett-Stabler, PhD | ||
| Vol 17, No 3 (2021): May/June | A program evaluation of Arkansas Improving Multidisciplinary Pain Care and Treatment (AR-IMPACT) | Abstract |
| Corey J. Hayes, PharmD, PhD, MPH, Heather R. Morgan, BS, Michael A. Cucciare, PhD, Masil George, MD, Johnathan H. Goree, MD, Teresa J. Hudson, PharmD, PhD, Shona L. Ray-Griffith, MD, Leah Tobey, PT, DPT, Mary Bollinger, PhD, KaSheena Winston, MS, Amanda Praseuth, BS, G. Richard Smith, MD | ||
| Vol 13, No 5 (2017): September/October | A public health outbreak management framework applied to surges in opioid overdoses | Abstract |
| Kieran Moore, MD, CCFP (EM), FCFP, MPH, DTM&H, FRCPC, Maximilien Boulet, BSc, Julia Lew, BSc, Nicholas Papadomanolakis-Pakis, BSocSc, MPA | ||
| Vol 13, No 1 (2017): January/February | A qualitative exploration of chronic pain and opioid treatment among HIV patients with drug use disorders | Abstract |
| Sarina R. Isenberg, MA, Allysha C. Maragh-Bass, MPH, PhD, Kathleen Ridgeway, MSPH, Mary Catherine Beach, MD, MPH, Amy R. Knowlton, MPH, ScD | ||
| Vol 14, No 3 (2018): May/June | A qualitative study to develop materials educating patients about opioid use before and after total hip or total knee arthroplasty | Abstract |
| David H. Smith, PhD, RPh, Jennifer Kuntz, PhD, Lynn DeBar, PhD, Jill Mesa, Xiuhai Yang, MS, David Boardman, MD, Jennifer Schneider, MPH | ||
| Vol 3, No 1 (2007): January/February | A randomized, open-label, multicenter trial comparing once-a-day AVINZA® (morphine sulfate extended-release capsules) versus twice-a-day OxyContin® (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: Improved physical functioning in the ACTION trial | Abstract PDF |
| Richard L. Rauck, MD, Stephen A. Bookbinder, MD, Timothy R. Bunker, MD, Christopher D. Alftine, MD, Steven Gershon, MD, Egbert de Jong, MD, Andres Negro-Vilar, MD, PhD, Richard Ghalie, MD | ||
| Vol 2, No 6 (2006): November/December | A randomized, open-label study of once-a-day AVINZA® (morphine sulfate extended-release capsules) versus twice-a-day OxyContin® (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: The extension phase of the ACTION trial | Abstract PDF |
| Richard L. Rauck, MD, Stephen A. Bookbinder, MD, Timothy R. Bunker, MD, Christopher D. Alftine, MD, Richard Ghalie, MD, Andres Negro-Vilar, MD, PhD, Egbert de Jong, MD, Steven Gershon, MD | ||
| Vol 6, No 3 (2010): May/June | A randomized, placebo-controlled, double-blinded, parallel-group, 5-week study of buprenorphine transdermal system in adults with osteoarthritis | Abstract |
| Catherine Munera, PhD, Margaret Drehobl, MD, Nelson E. Sessler, PharmD, Craig Landau, MD | ||
| Vol 1, No 1 (2005): March/April | A randomized trial of one-day vs. three-day buprénorphine inpatient detoxification protocols for heroin dependence | Abstract PDF |
| John A. Hopper, MD, Joanna Wu, BS, Wesley Martus, BS, James D. Pierre, MD | ||
| Vol 14, No 1 (2018): January/February | A Rasch analysis of the Current Opioid Misuse Measure for patients with chronic pain | Abstract |
| Courtney Morris, PhD, Kathy E. Green, PhD, Lilian L. Chimuma, MAT | ||
| Vol 8, No 2 (2012): March/April | A remifentanil/ketamine sedation in surgical cancer patients having severe Parkinson’s disease: Two case reports | Abstract |
| German Salazar, MD, Cyrus Motamed, MD | ||
| Vol 18, No 5 (2022): September/October | A retrospective analysis of the impact of Michigan's opioid prescribing legislation on discharge opioid prescribing at a single institution | Abstract |
| Richard Sadowski, MD, FHM, Emily Hillaker, DO, Michael Chavarria, MD, Fareea Khaliq, MD, Adam Schwark, MD | ||
| Vol 6, No 6 (2010): November/December | A retrospective chart review of opioid-induced nausea and somnolence on commencement for cancer pain treatment | Abstract |
| Yoshiaki Okamoto, BP, Satoru Tsuneto, MD, PhD, Mamiko Tsugane, PhD, Tatsuya Takagi, PhD, Etsuko Uejima, PhD | ||
| Vol 17, No 6 (2021): November/December | A retrospective study evaluating the trend of opioid prescribing in low back pain at a UK teaching hospital | Abstract |
| Ben Hunter, MBChB, BSc (Hons), Shiva Tripathi, MBBS, FRCA, CCT | ||
| Vol 8, No 3 (2012): May/June | A review of epidural and intrathecal opioids used in the management of postoperative pain | Abstract |
| Borja Mugabure Bujedo, MD, Silvia González Santos, MD, Amaia Uría Azpiazu, MD | ||
| Vol 10, No 3 (2014): May/June | A review of rapid-onset opioids for breakthrough pain in patients with cancer | Abstract |
| Steven M. Simon, RPh, MD, Lee S. Schwartzberg, MD, FACP | ||
| Vol 17, No 7 (2021): Special Issue - “Buprenorphine: Clinical and Public Policy Implications" | A review of the evidence to explain pharmacological basis of injection (ab)use of buprenorphine–naloxone tablets | Abstract |
| Tamoud Modak, MD, DM, Siddharth Sarkar, MD, MRCPsych, Yatan Pal Singh Balhara, MD | ||
| Vol 9, No 5 (2013): September/October | A review of the use of ketamine in pain management | Abstract |
| Qutaiba A. Tawfic, MBChB, FIBMS (Anesthesiology) | ||
| Vol 14, No 1 (2018): January/February | A snap shot of patients’ recall, attitudes, and perceptions of their pain contracts from a family medicine resident outpatient clinic | Abstract |
| Robinder Bahniwal, MD, Jarrett Sell, MD, Abdul Waheed, MD, FAAFP | ||
| Vol 2, No 2 (2006): March/April | A summary of current Drug Enforcement Administration positions and resulting federal legal and regulatory “standards” | Abstract PDF |
| Jennifer Bolen, JD | ||
| Vol 17, No 4 (2021): July/August | A survey assessment of clinician perceptions of opioid supply and monitoring requirement policy changes | Abstract |
| Amie Goodin, PhD, MPP, Juan M. Hincapie-Castillo, PharmD, MS, PhD, Joshua D. Brown, PharmD, PhD, Dikea Roussos-Ross, MD | ||
| Vol 7, No 1 (2011): January/February | A systematic compilation of reports published on opioid-related problems | Abstract |
| Matthew Butts, MD, Aminah Jatoi, MD | ||
| Vol 10, No 1 (2014): January/February | A systematic review of smartphone applications for chronic pain available for download in the United States | Abstract |
| Lorraine S. Wallace, PhD, Lara K. Dhingra, PhD | ||
| Vol 9, No 5 (2013): September/October | Aberrant behaviors in a primary care-based cohort of patients with chronic pain identified as misusing prescription opioids | Abstract |
| Martin D. Cheatle, PhD, Charles P. O’Brien, MD, PhD, Koshy Mathai, MD, Matthew Hansen, MD, Mario Grasso, MD, Peter Yi, MD | ||
| Vol 12, No 3 (2016): May/June | Abuse deterrence testing: A dose ratio escalation study examining naloxone coadministered with intravenous hydromorphone in non-treatment-seeking, opioid-dependent drug users | Abstract |
| Naama Levy-Cooperman, PhD, Kerri A. Schoedel, PhD, Joseph L. Reiz, BSc, David Thompson, PhD, Bijan Chakaraborty, MStat, Pierre Geoffroy, MD, Kenneth J. Michalko, PharmD, MBA | ||
| Vol 13, No 6 (2017): November/December - Abuse Deterrent Opioids Special Issue | Abuse Deterrent Opioids: Clinical and Public Policy Implications | Abstract |
| Richard A. DeVito, Jr | ||
| Vol 13, No 6 (2017): November/December - Abuse Deterrent Opioids Special Issue | Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder | Abstract |
| Theresa A. Cassidy, MPH, Eileen Thorley, MPH, Ryan A. Black, PhD, Angela DeVeaugh-Geiss, PhD, Stephen F. Butler, PhD, Paul Coplan, ScD | ||
| Vol 13, No 6 (2017): November/December - Abuse Deterrent Opioids Special Issue | Abuse-deterrent features of an extended-release morphine drug product developed using a novel injection-molding technology for oral drug delivery | Abstract |
| Nikolaj Skak, MS, Torben Elhauge, MSc, Jeffrey M. Dayno, MD, Karsten Lindhardt, MSc, PhD, DBE | ||
| Vol 13, No 6 (2017): November/December - Abuse Deterrent Opioids Special Issue | Abuse-deterrent formulations approval reform: Will clinical correctness or real-world results be used to address the nation's opioid crisis: “Noninterference” as a new approval standard | Abstract |
| Dan Cohen, MA/LS | ||
| Vol 13, No 6 (2017): November/December - Abuse Deterrent Opioids Special Issue | Abuse-deterrent formulations of opioids: Many questions still to answer | Abstract |
| Raeford E. Brown Jr, MD, FAAP | ||
| Vol 14, No 6 (2018): November/December | Abuse-deterrent properties of REMOXY® ER, a high-viscosity extended-release oxycodone formulation | Abstract |
| Shawn A. Kucera, PhD, Michael S. Zamloot, BS ChE, Michael M. Crowley, PhD, Lindsay H. Burns, PhD, Nadav Friedmann, PhD, MD, Remi Barbier, MBA | ||
| Vol 10, No 4 (2014): July/August | Academic family medicine physicians' confidence and comfort with opioid analgesic prescribing for patients with chronic nonmalignant pain | Abstract |
| Allison A. Macerollo, MD, Donald O. Mack, MD, Rupal Oza, MD, MPH, Ian M. Bennett, MD, PhD, Lorraine S. Wallace, PhD | ||
| Vol 12, No 3 (2016): May/June | Acceptability of the use of cellular telephone and computer pictures/video for “pill counts” in buprenorphine maintenance treatment | Abstract |
| Christopher Welsh, MD | ||
| Vol 12, No 1 (2016): January/February | Acetaminophen, a reasonable option, but not a panacea | Abstract |
| Xiulu Ruan, MD, Praveen Narahari, MD, MS, Alan D. Kaye, MD, PhD | ||
| Vol 10, No 6 (2014): November/December | Activity-based cost analysis of opioid-related nausea and vomiting among inpatients | Abstract |
| Leopold Eberhart, MD, Tilo Koch, MSc, Peter Kranke, MD, Dirk Rüsch, MD, Alexander Torossian, MD, Stefan Nardi-Hiebl, MBA | ||
| Vol 6, No 4 (2010): July/August | Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): Case report and the focused review of the literature | Abstract |
| Xiulu Ruan, MD, Tao Chen, MD, PhD, Jeff Gudin, MD, John Patrick Couch, MD, Srinivas Chiravuri, MD | ||
| Vol 5, No 4 (2009): July/August | ADDICTION VERSUS DEPENDENCE: CARRYING THE DEBATE FORWARD | Abstract |
| Yatan Pal Singh Balhara, MD, DNB, Shachi Mathur, MA, CHt, PhD Scholar | ||
| Vol 15, No 3 (2019): May/June | Addressing the opioid crisis: An assessment of clinicians’ training experience, practices, and attitudes within a large healthcare organization | Abstract |
| Harshal Kirane, MD, Elina Drits, DO, Seungjun Ahn, MS, Sandeep Kapoor, MD, Jonathan Morgenstern, PhD, Joseph Conigliaro, MD, Jay Enden, MD | ||
| Vol 12, No 5 (2016): September/October | Adherence to chronic opioid therapy prescribing guidelines in a primary care clinic | Abstract |
| Cynthia Kay, MD, MS, Erica Wozniak, MS, Sarah Koller, DO, Audrey Ye, MD, Joanne Bernstein, MD | ||
| Vol 16, No 4 (2020): July/August | Adjuvant interventions with opioids for vaso-occlusive crisis in sickle cell disease: A mixed treatment network meta-analysis of randomized controlled clinical trials | Abstract |
| Kannan Sridharan, MD, DM, Gowri Sivaramakrishnan, MDS | ||
| Vol 8, No 4 (2012): July/August | Advantages of EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended-release capsules in pain management | Abstract |
| Shailendra Kapoor, MD | ||
| Vol 2, No 3 (2006): May/June | Adverse effects and cognitive function among primary care patients taking opioids for chronic nonmalignant pain | Abstract PDF |
| Randall T. Brown, MD, Megan Zuelsdorff, BS, Michael Fleming, MD, MPH | ||
| Vol 17, No 7 (2021): Special Issue - “Buprenorphine: Clinical and Public Policy Implications" | Adverse effects of regulation on buprenorphine prescribing and its impact on the treatment of opioid use disorder | Abstract |
| Daniel M. Strickland, MD, FACOG, John Sorboro, MD, DABPN, FASAM | ||
| Vol 8, No 3 (2012): May/June | Affect of genetic polymorphisms on pain perception and pain management in lung cancer survivors | Abstract |
| Shailendra Kapoor, MD | ||
| Vol 15, No 1 (2019): January/February | Age differences in the association of nonmedical prescription opioid use and suicidality | Abstract |
| Keith T. Chan, MSW, PhD, Priya Winston, MSW, Rubin Jennings, MS, Jeffrey Trant, MSW, Mary Moller, MSW | ||
| Vol 9, No 2 (2013): March/April | Age, gender, and earlier opioid requirement associations with the rate of dose escalation in long-term opioid therapy | Abstract |
| Huijun Han, MD, PhD, Philip H. Kass, DVM, PhD, Barth L. Wilsey, MD, Chin-Shang Li, PhD | ||
| Vol 17, No 4 (2021): July/August | Age-related prescription medication utilization for the management of sickle cell disease among Texas Medicaid patients | Abstract |
| Nidhi Shukla, MS, MBA, Jamie C. Barner, PhD, FAACP, FAPhA, Kenneth A. Lawson, PhD, FAPhA, Karen L. Rascati, PhD | ||
| Vol 17, No 7 (2021): Special Issue - “Buprenorphine: Clinical and Public Policy Implications" | Alan Cowan: Buprenorphine from the bench to the bedside—Personal notes | Abstract |
| Saadet Inan, MD, PhD, Michael Guarnieri, PhD, MPH | ||
| Vol 15, No 4 (2019): July/August | An Acute Pain Service experience initiating methadone for opioid use disorder in hospitalized patients with acute pain | Abstract |
| Rebecca C. Dale, DO, Carol L. Metcalf, MN, ARNP, Dale J. Langford, Christina E. Bockman, PharmD, Debra B. Gordon, DNP, RN, FAAN, Daniel L. Krashin, MD, Katherin A. Peperzak, MD, Andrea K. Breuner, PA-C, Michelle C. Accardi-Ravid, PhD, Ivan K. Lesnik, MD | ||
| Vol 13, No 1 (2017): January/February | An analysis of errors, discrepancies, and variation in opioid prescriptions for adult outpatients at a teaching hospital | Abstract |
| Mark C. Bicket, MD, Deepa Kattail, MD, Myron Yaster, MD, Christopher L. Wu, MD, Peter Pronovost, MD, PhD | ||
| Vol 10, No 3 (2014): May/June | An evaluation of the performance of the Opioid Manager clinical tool in primary care: A qualitative study | Abstract |
| Andrew Robertson, BSc, MD (Candidate), Sander L. Hitzig, PhD, Andrea D. Furlan, MD, PhD | ||
| Vol 3, No 5 (2007): September/October | An evaluation of the predictive validity of the Pain Medication Questionnaire with a heterogeneous group of patients with chronic pain | Abstract |
| Leah S. Dowling, MS, Robert J. Gatchel, PhD, Laura L. Adams, PhD, Anna W. Stowell, PhD, Dana Bernstein, MS, PhD | ||
| Vol 7, No 1 (2011): January/February | An improved method of determining ethanol use in a chronic pain population | Abstract |
| Bridgit Crews, PhD, Robert West, MS, Ronita Gutierrez, CLS, Sergey Latyshev, MS, Charles Mikel, PhD, Perla Almazan, CLS, MT (ASCP), Amadeo Pesce, PhD, DABCC, Cameron West, PhD, Murray Rosenthal, DO, FAPA | ||
| Vol 8, No 6 (2012): November/December | An open-label pharmacokinetic study of oxymorphone extended release in the presence of naltrexone in the older adult | Abstract |
| Joseph V. Pergolizzi Jr, MD, Robert B. Raffa, PhD, Robert Taylor Jr, PhD, Swati Nagar, PhD, Sumedha Labhsetwar, MD, Nicholas Sinclair, MD, Errol M. Gould, PhD | ||
| Vol 16, No 3 (2020): May/June | An open-label, randomized, single-dose, two-period, two-treatment crossover bioavailability study comparing 5 mg/0.5 mL of intramuscular naloxone hydrochloride to 2 mg/0.4 mL intramuscular naloxone hydrochloride autoinjector in healthy subjects | Abstract |
| Ronald B. Moss, MD, Fiona Carleton, PhD, Charles P. Lollo, PhD, Dennis J. Carlo, PhD | ||
| Vol 16, No 2 (2020): March/April | An overview on medication-assisted treatment (MAT) for opioid dependence | Abstract |
| Tanay Maiti, DPM, DNB, Saibal Das, MD, Anand Ramasamy, MPharm, Alphienes Stanley Xavier, MD, DM, DNB, Sapan Kumar Behera, MD, DM, Sandhiya Selvarajan, MD, DM, DNB | ||
| Vol 17, No 6 (2021): November/December | Analgesia vs. addiction | Abstract |
| Tyler Coyle, MD, MS, Tyler J. Tantillo, DO | ||
| Vol 7, No 3 (2011): May/June | Analgesic and adverse effects of a fixed-ratio morphine-oxycodone combination (MoxDuo®) in the treatment of postoperative pain | Abstract |
| Patricia Richards, MD, PhD, Dennis Riff, MD, Robin Kelen, RN, Warren Stern, PhD | ||
| Vol 3, No 3 (2007): May/June | Analgesic effects of lornoxicam after total abdominal hysterectomy | Abstract PDF |
| Ozgur Sapolya, MD, Beyhan Karamanlhoglu, MD, Dilek Memis, MD | ||
| Vol 7, No 4 (2011): July/August | Analgesic efficacy of intravenous naloxone for the treatment of postoperative pruritus: A meta-analysis | Abstract |
| Jamie D. Murphy, MD, Harold J. Gelfand, MD, Mark C. Bicket, MD, Jean-Pierre P. Ouanes, DO, Kanupriya K. Kumar, MD, Gillian R. Isaac, MD, PhD, Christopher L. Wu, MD | ||
| Vol 7, No 4 (2011): July/August | Analgesic treatment for moderate-to-severe acute pain in the United States: Patients’ perspectives in the Physicians Partnering Against Pain (P3) Survey | Abstract |
| Bruce L. Moskovitz, MD, Carmela J. Benson, MS, Aarti A. Patel, MBA, PharmD, Wing Chow, MPH, PharmD, Samir H. Mody, MBA, PharmD, Bill H. McCarberg, MD, Myoung S. Kim, MBA, MA, PhD | ||
| Vol 12, No 2 (2016): March/April | Analgesic utilization before and after rescheduling of hydrocodone in a large academic level 1 trauma center | Abstract |
| Steven Schultz, PharmD, Carol Chamberlain, PharmD, Psych MA, Marius Vulcan, MD, Humair Rana, MD, Bhavin Patel, PharmD, MBA, John C. Alexander, MD | ||
| Vol 18, No 4 (2022): July/August | Analysis of pediatric opioid analgesics prescribed in a large pediatric hospital over a 5-year period | Abstract |
| Soheil Saadat, MD, MPH, PhD, Nikhil Shah, BS, Shivam Patel, BS, Rishi Bhargava, MD, Campbell Belisle Haley, MD, Bharath Chakravarthy, MD, MPH | ||
| Vol 7, No 3 (2011): May/June | Analysis of the paramedic administration of fentanyl | Abstract |
| Jocelyn Freeman Garrick, MD, FACEP, Senai Kidane, MD, EMS Fellow, James E. Pointer, MD, William Sugiyama, MA, RN, NREMT-P, Christopher Van Luen, EMT-P, Rebecca Clark, EMT-B | ||
| Vol 12, No 1 (2016): January/February | Analyzing the relationship between nonmedical prescription-opioid use and heroin use | Abstract |
| Xiulu Ruan, MD, Melville Q. Wyche, III, MD, Alan David Kaye, MD, PhD | ||
| Vol 17, No 5 (2021): September/October | Analyzing the relationships between city opioid deaths and socioeconomic factors | Abstract |
| Ryan William McGinnis, MS, Les Sztandera, PhD, Jeanne Ruane, PhD, Rajanikanth Vadigepalli, PhD | ||
| Vol 19, No 2 (2023): March/April | Appendix: Impact of the extended-release/long-acting opioid analgesics risk evaluation and mitigation strategy on prescribing practices - Appendix | Abstract |
| Matthew H. Secrest, MSc, Syd Phillips, MPH, M. Soledad Cepeda, MD, PhD, David M. Kern, MS, PhD, Daina B. Esposito, MPH, PhD, Gregory P. Wedin, PharmD | ||
| Vol 13, No 6 (2017): November/December - Abuse Deterrent Opioids Special Issue | Application of hot-melt extrusion technology in immediate-release abuse-deterrent formulations | Abstract |
| Klaus Wening, PhD, Sebastian Schwier, PhD, Hans-J. Stahlberg, MD, Eric Galia, PhD | ||
| Vol 6, No 4 (2010): July/August | Applying partially occluded fentanyl transdermal patches to manage pain in pediatric patients | Abstract |
| Amy Mitchell, PharmD, Howard S. Smith, MD | ||
| Vol 14, No 4 (2018): July/August | Are physicians fully aware of the potential transgenerational and multigenerational effects of a large opioid misuse in the population? | Abstract |
| Maurizio Coppola, MD, Raffaella Mondola, MD | ||
| Vol 3, No 3 (2007): May/June | Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia | Abstract PDF |
| Dana Tarcatu, MD, Cristina Tamasdan, MD, Natalie Moryl, MD, Eugenie Obbens, MD, PhD | ||
| Vol 16, No 2 (2020): March/April | Aromatherapy as an adjunctive therapy for neonatal abstinence syndrome: A pilot study | Abstract |
| John M. Daniel, IV, MD, MS, Lesley N. Davidson, MD, MS, Jennifer R. Havens, PhD, MPH, John A. Bauer, PhD, Lori A. Shook, MD | ||
| Vol 3, No 6 (2007): November/December | Arrested on heroin: A national opportunity | Abstract |
| Amy E. Boutwell, MD, MPP, Ank Nijhawan, MD, Nickolas Zaller, PhD, Josiah D. Rich, MD, MPH | ||
| Vol 18, No 2 (2022): March/April | Assessing coprescription of opioids with central nervous system depressants for nonmalignant chronic musculoskeletal pain management in the outpatient setting | Abstract |
| Rana Zalmai, PharmD, Walter Agbor Bawa, PharmD, Meredith Howard, PharmD, Rafia S. Rasu, PhD | ||
| Vol 14, No 5 (2018): September/October | Assessing risk of opioid misuse in the treatment of chronic pain: Building a practical actuarial approach | Abstract |
| David M. Erekson, PhD, Liliana Bautista, Dallin Albright | ||
| Vol 8, No 5 (2012): September/October | Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users | Abstract |
| Kerri A. Schoedel, PhD, Robert L. Rolleri, PharmD, Janice Y. Faulknor, MD, CCFP, Glenn C. Pixton, MS, Nancy Chen, PhD, Almasa Bass, PharmD, Kenneth W. Sommerville, MD, Edward Sellers, MD, PhD, FRCPC, FACP | ||
| Vol 13, No 3 (2017): May/June | Assessing the impact of the extended-release/long-acting opioid analgesics risk evaluation and mitigation strategies on opioid prescription volume | Abstract |
| Victoria Divino, BA, M. Soledad Cepeda, MD, PhD, Paul Coplan, ScD, MBA, MPH, Jean-Yves Maziere, MD, PhD, Yingli Yuan, PhD, Rolin L. Wade, RPh, MS | ||
| Vol 12, No 6 (2016): November/December | Assessment of abuse liability of Tramadol among experienced drug users: Double-blind crossover randomized controlled trial | Abstract |
| Mrinmay Das, MBBS, MD, Raka Jain, MSc, PhD, CChem FRSC (UK), Anju Dhawan, MBBS, MD, Amandeep Kaur, MBBS, MD | ||
| Vol 12, No 5 (2016): September/October | Assessment of acute pain in trauma—A retrospective prehospital evaluation | Abstract |
| Stine Hebsgaard, MD, Anne Mannering, MD, Stine T. Zwisler, MD, PhD | ||
| Vol 14, No 2 (2018): March/April | Assessment of outcomes following high-dose opioid tapering in a Veterans Healthcare System | Abstract |
| Lauren Hundley, PharmD, BCPS, Shelley Spradley, PharmD, BCPS, Scott Donelenko, BPharm, CPE | ||
| Vol 17, No 3 (2021): May/June | Assessment of post-operative opioid prescribing practices in a community hospital ambulatory surgical center | Abstract |
| Warren D. Bromberg, MD, FACS, Tracey Emanuel, MSN, RN, FNP-BC, Valerie Zeller, MA, RN, Elizabeth Galloway, BSN, RN, CAPA, Susan Mogan, DNP, ANP-BC, ACHPN, AP-PMN, Justin Diamond, BS, Debra Statler, RN III-C, BC, Fay Wright, PhD, RN, APRN-BC | ||
| Vol 8, No 6 (2012): November/December | Assessment of the abuse of tapentadol immediate release: The first 24 months | Abstract |
| Richard C. Dart, MD, PhD | ||
| Vol 11, No 5 (2015): September/October | Assessment of the use of oral fluid as a matrix for drug monitoring in patients undergoing treatment for opioid addiction | Abstract |
| Frank Kunkel, MD, Elizabeth Fey, MS, Damon Borg, PhD, Richard Stripp, PhD, Christine Getto, BS | ||
| Vol 7, No 6 (2011): November/December | Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting | Abstract |
| James Brown, MD, Beatrice Setnik, PhD, Keung Lee, MD, PhD, Linda Wase, MD, Carl L. Roland, PharmD, Jody M. Cleveland, MS, Sherry Siegel, MD, Nathaniel Katz, MD, MS | ||
| Vol 14, No 4 (2018): July/August | Association between the North Carolina Medical Board opioid guideline update and opioid prescriptions in Medicare Part D beneficiaries | Abstract |
| Chris Gillette, PhD, Mark A. Bush, PhD, Kate M. L. Rogers, PharmD Candidate, Geoffrey Mospan, PharmD, BCPS, Kimberly Nealy, PharmD, BCPS, CDE, CPP, Michelle DeGeeter, PharmD, BCACP, CDE, April M. Robinson, PharmD, BCPS | ||
| Vol 17, No 6 (2021): November/December | Association of opioid exposure during intensive care unit stays with post-discharge opioid use: A retrospective study and literature review | Abstract |
| Yoonsun Mo, MS, PharmD, BCPS, BCCCP, John Zeibeq, MD, Nabil Mesiha, MD, Abou Bakar, PharmD, Maram Sarsour, PharmD, Michelle Liu, PharmD, James Gasperino, MD, PhD, MPH, DABT | ||
| Vol 18, No 5 (2022): September/October | Association of request for opioid medications refill after hospital discharge with race in patients with prostate cancer treated with robotic-assisted laparoscopic radical prostatectomy | Abstract |
| Shaheen Alanee, MD, Diana Chammout, Mustafa Deebajah, MD, James Peabody, Mani Menon | ||
| Vol 4, No 2 (2008): March/April | Association of transdermal fentanyl and oral transmucosal fentanyl citrate in the treatment of opioid naïve patients with severe chronic noncancer pain | Abstract |
| Francisco Collado, MD, PhD, Luis M. Torres, MD, PhD | ||
| Vol 14, No 3 (2018): May/June | Associations between pain coping and opioid use: One-month follow-up results of a prospective study in a cohort of traumatic injury patients | Abstract |
| Jordan C. Smith, BS, Christopher R. Nicholas, PhD, Scott J. Hetzel, MS, Bri M. Deyo, MPH, Randall T. Brown, MD, PhD | ||
| Vol 9, No 1 (2013): January/February | Associations between public health indicators and injecting prescription opioids by prescription opioid abusers in substance abuse treatment | Abstract |
| Ryan A. Black, PhD, Kimberlee J. Trudeau, PhD, Theresa A. Cassidy, MPH, Simon H. Budman, PhD, Stephen F. Butler, PhD | ||
| Vol 15, No 3 (2019): May/June | Attitudes and self-reported practices of orthopedic providers regarding prescription opioid use | Abstract |
| Deepa Kattail, MD, MHS, Aaron Hsu, MHS, Myron Yaster, MD, Paul T. Vozzo, BA, Shuna Gao, BA, John M. Thompson, MD, Debra L. Roter, DrPH, Dawn Laporte, MD, R. Frank Henn 3rd, MD, John E. Fiadjoe, MD, Constance L. Monitto, MD | ||
| Vol 12, No 6 (2016): November/December | Attitudes toward the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain: A qualitative study | Abstract |
| Yaping Chang, MSc, Kan Lun Zhu, Ivan D. Florez, MD, MSc, Sung Min Cho, BHSc, Nasim Zamir, HBSc, Augustin Toma, BESc, Reza Donald Mirza, MD, Gordon H. Guyatt, MD, MSc, Norman Buckley, MD, Jason W. Busse, DC, PhD | ||
| Vol 3, No 5 (2007): September/October | Attributes and behaviors associated with opioid seeking in the emergency department | Abstract |
| Lisa Chan, MD, Billie Winegard, MPH | ||
| Vol 17, No 7 (2021): Special Issue - “Buprenorphine: Clinical and Public Policy Implications" | Atypical opioids and their effect on respiratory drive | Abstract |
| Lynn Webster, MD, Richard L. Rauck, MD | ||
| Vol 6, No 1 (2010): January/February | AWAKE FIBEROPTIC INTUBATION WITH TARGET-CONTROLLED INFUSION OF REMIFENTANIL IN EMERGENCY SURGERY | Abstract |
| Cyrus Motamed, MD, German Salazar, MD | ||
| Vol 9, No 6 (2013): November/December | Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program | Abstract |
| Pooja A. Shah, BS, Nancy L. Sohler, PhD, MPH, Carolina López, BA, Aaron D. Fox, MD, Chinazo O. Cunningham, MD, MS | ||
| Vol 15, No 4 (2019): July/August | “We get tunnel vision”: Emergency medical service providers’ views on the opioid epidemic in Baltimore City | Abstract |
| Allysha C. Maragh-Bass, PhD, MPH, Julie C. Fields, MD, PhD, Zachary Catanzarite, MA, Amy R. Knowlton, ScD, MPH | ||
| Vol 4, No 5 (2008): September/October | Balanced anesthesia with remifentanil and desflurane: Clinical considerations for dose adjustment in adults | Abstract |
| Ralph Nöst, MD, Antje Thiel-Ritter, MD, Stefan Scholz, MD, Gunter Hempelmann, MD, Matthias Müller, MD | ||
| Vol 11, No 5 (2015): September/October | Balancing opioid-induced gastrointestinal side effects with pain management: Insights from the online community | Abstract |
| Cynthia B. Whitman, MPH, Mark W. Reid, PhD, Corey Arnold, PhD, Lyann Ursos, PhD, Roee Sa’adon, MS, Jonathan Pourmorady, MD, Brennan M. R. Spiegel, MD, MSHS, Haridarshan Patel, PharmD | ||
| Vol 2, No 1 (2006): January/February | Barriers and facilitators to methadone maintenance therapy use among illicit opiate injection drug users in Vancouver | Abstract PDF |
| Cody Callon, BSc, Evan Wood, PhD, David Marsh, MD, Kathy Li, PhD, Julio Montaner, MD, Thomas Kerr, PhD | ||
| Vol 10, No 6 (2014): November/December | Beliefs and attitudes about opioid prescribing and chronic pain management: Survey of primary care providers | Abstract |
| Robert N. Jamison, PhD, Kerry Anne Sheehan, BA, Elizabeth Scanlan, NP, Michele Matthews, PharmD, Edgar L. Ross, MD | ||
| Vol 7, No 6 (2011): November/December | Beliefs and attitudes about prescribing opioids among healthcare providers seeking continuing medical education | Abstract |
| W. Michael Hooten, MD, Barbara K. Bruce, PhD | ||
| Vol 7, No 2 (2011): March/April | Bioequivalence and safety of a novel fentanyl transdermal matrix system compared with a transdermal reservoir system | Abstract |
| Kenneth Todd Moore, MS, Holly D. Adams, MS, Jaya Natarajan, PhD, Jay Ariyawansa, MS, Henry M. Richards, MD | ||
| Vol 15, No 1 (2019): January/February | Biopsychosocial determinants of opioid use disorder (OUD) and implications for maternal and child health research: A scoping review | Abstract |
| Hamisu M. Salihu, MD, PhD, Abraham Salinas, MD, PhD, Imelda Medina, MD, MPH, Janani Krishnaswami, MD, MPH, Muktar H. Aliyu, MD, DrPH | ||
| Vol 15, No 5 (2019): September/October | Birth outcomes with prescribed chronic and acute opioid exposure during pregnancy | Abstract |
| Thomas Delate, PhD, MS, Megan Hodges, PharmD, Morgan Swank, MD, Taylor Ota, PharmD Candidate, Christy L. Pratt, PharmD | ||
| Vol 15, No 5 (2019): September/October | "Blister packs" rather than "ashes to ashes, dust to dust" for medications | Abstract |
| Deepak Gupta, MD, Shushovan Chakrabortty, MD, PhD | ||
| Vol 6, No 2 (2010): March/April | Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, Part 1: Prevalence and characteristics | Abstract |
| Russell K. Portenoy, MD, Daniel Bruns, PsyD, Bonnie Shoemaker, BSN, Steven A. Shoemaker, MD | ||
| Vol 6, No 2 (2010): March/April | Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, Part 2: Impact on function, mood, and quality of life | Abstract |
| Russell K. Portenoy, MD, Daniel Bruns, PsyD, Bonnie Shoemaker, BSN, Steven A. Shoemaker, MD | ||
| Vol 2, No 6 (2006): November/December | Breakthrough pain in opioid-treated patients with neuropathic pain | Abstract PDF |
| Steve Simon, MD, RPh, Daniel S. Bennett, MD, Richard Rauck, MD, Donald Taylor, MD, Steven Shoemaker, MD | ||
| Vol 19, No 1 (2023): January/February | Building a community of experts in medication-assisted treatment (MAT) using the Project ECHO© model | Abstract |
| Justin P. Canakis, DO, Matthew P. Momjian, BA, Faraz Yousefian, DO, Hayden Pond, BS, Adrienne White, MS, Gregory Mayer, MD, Alison C. Essary, DHSc, PA-C | ||
| Vol 17, No 7 (2021): Special Issue - “Buprenorphine: Clinical and Public Policy Implications" | Buprenorphine blood concentrations: A biomarker for analgesia | Abstract |
| Michael Guarnieri, PhD, MPH | ||
| Vol 16, No 6 (2020): November/December | Buprenorphine maintenance treatment in patients with opioid use disorder diagnosed with COVID-19 | Abstract |
| Michael Frost, MD, FACP, FASAM | ||
| Vol 17, No 7 (2021): Special Issue - “Buprenorphine: Clinical and Public Policy Implications" | Buprenorphine not a silver bullet but an opioid of choice for chronic pain | Abstract |
| Mellar P. Davis, MD, FCCP, FAAHPM, Jeffrey Fudin, PharmD, FACCP, FASHP, FFSMB | ||
| Vol 17, No 7 (2021): Special Issue - “Buprenorphine: Clinical and Public Policy Implications" | Buprenorphine not detected on urine drug screening in supervised treatment | Abstract |
| Nazila Jamshidi, MBBS, FRACP, FAChAM, BPharm (hons), PhD, Akshay Athavale, MBBS, FRACP, BPharm (hons), MMed, Bridin Murnion, MBChB, FRACP, FFPMANZCA, FAChAM | ||
| Vol 8, No 1 (2012): January/February | Buprenorphine therapy for opioid addiction in rural Washington: The experience of the early adopters | Abstract |
| Tyler L. Quest, BS, Joseph O. Merrill, MD, John Roll, PhD, Andrew J. Saxon, MD, Roger A. Rosenblatt, MD, MPH | ||
| Vol 5, No 1 (2009): January/February | Buprenorphine: A review | Abstract |
| Sidarth Wakhlu, MD | ||
| Vol 3, No 1 (2007): January/February | Buprenorphine: A unique opioid with broad clinical applications | Abstract PDF |
| Nalini Vadivelu, MD, Roberta L. Hines, MD | ||
| Vol 17, No 7 (2021): Special Issue - “Buprenorphine: Clinical and Public Policy Implications" | Buprenorphine: Clinical and Public Policy Implications | Abstract |
| Journal of Opioid Management | ||
| Vol 17, No 7 (2021): Special Issue - “Buprenorphine: Clinical and Public Policy Implications" | Buprenorphine: Not a silver bullet, and still controversial | Abstract |
| Sudheer Potru, DO, FASAM, Michael Sprintz, DO, DFASAM, Antje M. Barreveld, MD, Lynn Kohan, MD | ||
| Vol 3, No 4 (2007): July/August | Buprenorphine—A review of its role in neuropathic pain | Abstract |
| Guy Hans, MD | ||
| Vol 6, No 4 (2010): July/August | Burden of opioid-associated gastrointestinal side effects from clinical and economic perspectives: A systematic literature review | Abstract |
| Kim Boswell, MD, Winghan Jacqueline Kwong, PharmD, PhD, Shane Kavanagh, MSc | ||
| Vol 1, No 1 (2005): March/April | Calendar | Abstract PDF |
| Richard A. DeVito, Jr. | ||
| Vol 1, No 2 (2005): May/June | Calendar | Abstract PDF |
| Richard A. DeVito, Jr. | ||
| Vol 1, No 3 (2005): July/August | Calendar | Abstract PDF |
| Richard A. DeVito, Jr. | ||
| Vol 1, No 4 (2005): September/October | Calendar | Abstract PDF |
| Richard A. DeVito, Jr. | ||
| Vol 1, No 5 (2005): November/December | Calendar | Abstract PDF |
| Richard A. DeVito, Jr. | ||
| Vol 2, No 1 (2006): January/February | Calendar | Abstract PDF |
| Richard A. DeVito, Jr. | ||
| Vol 2, No 2 (2006): March/April | Calendar | Abstract PDF |
| Richard A. DeVito, Jr. | ||
| Vol 2, No 3 (2006): May/June | Calendar | Abstract PDF |
| Richard A. DeVito, Jr. | ||
| Vol 2, No 4 (2006): July/August | Calendar | Abstract PDF |
| Richard A. DeVito, Jr. | ||
| Vol 2, No 5 (2006): September/October | Calendar | Abstract PDF |
| Richard A. DeVito, Jr. | ||
| Vol 3, No 1 (2007): January/February | Calendar | Abstract PDF |
| Richard A. DeVito, Jr. | ||
| Vol 3, No 2 (2007): March/April | Calendar | Abstract PDF |
| Richard A. DeVito, Jr. | ||
| Vol 12, No 4 (2016): July/August | Call For Papers - Special Abuse Deterrent Formulation Issue | Abstract |
| Lynn Webster, MD | ||
| Vol 12, No 4 (2016): July/August | Call for Proposals for Papers, Posters, Presentations, Symposia and Corporate Satellite Symposia for ICOO2017 | Abstract |
| Paul Sloan, MD | ||
| Vol 13, No 3 (2017): May/June | Can 28-day prescription prevent unintentional medication surplus with 30-day prescription? | Abstract |
| Deepak Gupta, MD, Shushovan Chakrabortty, MD, PhD | ||
| Vol 16, No 2 (2020): March/April | Can opioid vigilance and patient-centered care coexist? A qualitative study of communicative tensions encountered by surgical trainees | Abstract |
| Elizabeth Troutman Adams, MA, Elisia L. Cohen, PhD, Andrew Bernard, MD, Whittney H. Darnell, PhD, Douglas R. Oyler, PharmD | ||
| Vol 5, No 5 (2009): September/October | Can the cognitively impaired safely use patient-controlled analgesia? | Abstract |
| Eugene Licht, MD, Eugenia L. Siegler, MD, M. Carrington Reid, MD, PhD | ||
| Vol 17, No 5 (2021): September/October | Can the implementation of the Opioid Start Talking form impact the amount of opioid use in patients after ankle fracture repair? | Abstract |
| Benjamin Best, DO, Alan Afsari, MD, Rajan Sharma, DO, James T. Layson, DO, Marek Denisiuk, DO | ||
| Vol 3, No 1 (2007): January/February | Can we continue to do business as usual? | Abstract PDF |
| B. Eliot Cole, MD, MPA | ||
| Vol 8, No 3 (2012): May/June | Cancer pain in the opioid-addicted patient: Can we treat it right? | Abstract |
| Vania Modesto-Lowe, MD, MPH, Lisa Girard, BS, MHS, PA-C, Margaret Chaplin, MD | ||
| Vol 4, No 6 (2008): November/December | Cancer pain management at a tertiary care cancer center in India—A retrospective analysis of 3,238 patients | Abstract |
| Sushma Bhatnagar, MD, Seema Mishra, MD, Madhurima Srikanti, MD, Deepak Gupta, MD | ||
| Vol 16, No 3 (2020): May/June | Cannabidiol (CBD) as a treatment of acute and chronic back pain: A case series and literature review | Abstract |
| Jonathan P. Eskander, MD, MBA, Junaid Spall, BS, Awais Spall, BA, Rinoo V. Shah, MD, MBA, Alan D. Kaye, MD, PhD | ||
| Vol 2, No 4 (2006): July/August | Capnography monitoring during opioid PCA administration | Abstract PDF |
| Rob Hutchison, PharmD | ||
| Vol 16, No 2 (2020): March/April | Caregiver-fabricated illness in a child prescribed long-term opioids and benzodiazepines | Abstract |
| Deepa Kattail, MD, MHS, FAAP, Anne Niec, MD, FRCPC | ||
| Vol 18, No 4 (2022): July/August | Case of buprenorphine-associated central sleep apnea resolving with dose reduction | Abstract |
| Vladimir Tchikrizov, MD, Allen C. Richert, Jr, MD, Saurabh B. Bhardwaj, MD | ||
| Vol 10, No 2 (2014): March/April | Case study investigating effect of implementing strategies for Reducing patient complaints in an outpatient pain clinic | Abstract |
| Cheryl D. Bernstein, MD, Mohammed Khan, MD, Adeel Haq, MD, Nadia Olszanski, RN, Dawn A. Marcus, MD | ||
| Vol 8, No 6 (2012): November/December | Case Study. Transdermal buprenorphine controls central neuropathic pain | Abstract |
| Michelle Weiner, DO, MPH | ||
| Vol 12, No 4 (2016): July/August | Caveat emptor: Erroneous safety information about opioids in online drug-information compendia | Abstract |
| Sonia R. Talwar, PharmD, Amarita S. Randhawa, PharmD, Erica H. Dankiewicz, PharmD, Nancy T. Crudele, PharmD, J. David Haddox, DDS, MD | ||
| Vol 6, No 6 (2010): November/December | Cerebral measurements and their correlation with the onset age and the duration of opioid abuse | Abstract |
| Reetta Kivisaari, MD, PhD, Pekka Rapeli, Psyc. Lic., Koen Van Leemput, PhD, Seppo Kähkönen, MD, PhD, Varpu Puuskari, MD, Olga Jokela, MD, Taina Autti, MD, PhD | ||
| Vol 18, No 4 (2022): July/August | Change of quality of life in patients with chronic pain with prescription opioid usage after opioid detoxification | Abstract |
| Gabija Laubner, MD, PhD Student, Beatričė Zakarauskaitė, MD, Gabrielė Pociuvienė, MD, Rokas Tamošauskas, MD, Robertas Badaras, PhD | ||
| Vol 16, No 6 (2020): November/December | Changes in opioid prescriptions for Medicaid-enrolled children and young adults, 2012-2016 | Abstract |
| Abbey Masonbrink, MD, MPH, Troy Richardson, PhD, Jennifer Delzeit, BS, Melissa K. Miller, MD, MSc, Matt Hall, PhD, Delwyn Catley, PhD, MS | ||
| Vol 13, No 4 (2017): July/August | Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse | Abstract |
| Bernd A. Wollschlaeger, MD, FAAFP, FASAM, Tina M. Willson, PhD, Leslie B. Montejano, MA, CCRP, Naoko A. Ronquest, PhD, Vijay R. Nadipelli, BPharm, MS | ||
| Vol 7, No 5 (2011): September/October | Characteristics of a nontreatment-seeking sample of over-the-counter codeine users: Implications for intervention and prevention | Abstract |
| Suzanne Nielsen, BPharm, BPharmSc (Hons), PhD, Jacqui Cameron, BA, BSW, MPhil (Social Science Research), Nicole Lee, BSc (Hons), GradCertEd (Tertiary), PhD, MAPS | ||
| Vol 5, No 5 (2009): September/October | Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State | Abstract |
| Sunil K. Aggarwal, PhD, MD Candidate, Gregory T. Carter, MD, MS, Mark D. Sullivan, MD, PhD, Craig ZumBrunnen, PhD, Richard Morrill, PhD, Jonathan D. Mayer, PhD | ||
| Vol 8, No 5 (2012): September/October | Characteristics of prescribers whose patients shop for opioids: Results from a cohort study | Abstract |
| M. Soledad Cepeda, MD, PhD, Daniel Fife, MD, Jesse A. Berlin, ScD, Gregory Mastrogiovanni, BS, Yingli Yuan, PhD | ||
| Vol 6, No 4 (2010): July/August | Characteristics of prescription opioid abusers in treatment: Prescription opioid use history, age, use patterns, and functional severity | Abstract |
| Stephen F. Butler, PhD, Ryan A. Black, PhD, Jill M. Grimes Serrano, PhD, Mollie E. Wood, MPH, Simon H. Budman, PhD | ||
| Vol 14, No 5 (2018): September/October | Characteristics of prior emergency departments visits associated with subsequent opioid overdose | Abstract |
| Elias Youssef, MD, MBA, Han Tony Gao, MD, Conor Russell, MD, Shorok Hassan, MD, Brahim Ardolic, MD, Barry Hahn, MD | ||
| Vol 19, No 1 (2023): January/February | Characterization of early versus late opioid iatrogenic withdrawal syndrome in critically ill children transitioning from fentanyl infusions to methadone | Abstract |
| Trager D. Hintze, PharmD, Jamie L. Miller, PharmD, BCPS, BCPPS, FPPA, Stephen B. Neely, MPH, Sin Yin Lim, PharmD, MS, Neha Gupta, MD, FAAP, Peter N. Johnson, PharmD, BCPS, BCPPS, FPPA, FCCM, FASHP | ||
| Vol 9, No 6 (2013): November/December | Characterization of opioid overdose and response in a high-risk community corrections sample: A preliminary study | Abstract |
| Karen L. Cropsey, PsyD, Stephen Martin, MD, EdM, C. Brendan Clark, PhD, Cheryl B. McCullumsmith, MD, PhD, Peter S. Lane, DO, Sonya Hardy, MS, Peter S. Hendricks, PhD, Nicole Redmond, MD, PhD, MPH | ||
| Vol 18, No 1 (2022): January/February | Chemical stability of naloxone products beyond their labeled expiration dates | Abstract |
| Mohammad F. Hossain, PhD, Mamoon Rashid, PhD, Randy Mullins, PharmD, Tiffany Davis, PharmD, Craig Kimble, PharmD, MBA, MS, BCACP, Sushanta Sarkar, MS, PharmD, Charles “CK” Babcock, PharmD, CDE, BCACP | ||
| Vol 1, No 5 (2005): November/December | Cholecystokinin antagonists: Can they augment opioid-derived analgesia? | Abstract PDF |
| Gary McCleane, MD | ||
| Vol 11, No 1 (2015): January/February | Choosing the right laboratory: A review of clinical and forensic toxicology services for urine drug testing in pain management | Abstract |
| Gary M. Reisfield, MD, Bruce A. Goldberger, PhD, Roger L. Bertholf, PhD | ||
| Vol 5, No 5 (2009): September/October | Chronic opioid therapy issues associated with opioid abuse potential | Abstract |
| Howard S. Smith, MD, Kenneth L. Kirsh, PhD, Steven D. Passik, PhD | ||
| Vol 12, No 4 (2016): July/August | Clinical analgesia correlates with decline in temporal summation in response to remifentanil infusion in patients with chronic neuropathic (radicular) pain | Abstract |
| Erica Suzan, PhD, Ayelet Midbari, MD, Dorit Pud, PhD, Salim Hadad, PhD, Elon Eisenberg, MD | ||
| Vol 9, No 6 (2013): November/December | Clinical applications of oxymorphone | Abstract |
| Nalini Vadivelu, MD, Monisa Maria, MBBS, Suneil Jolly, MD, Julia Rosenbloom, MD, Arun Prasad, MD, Alan David Kaye, MD, PhD | ||
| Vol 8, No 4 (2012): July/August | Clinical effectiveness and safety of OROS® hydromorphone in breakthrough cancer pain treatment: A multicenter, prospective, open-label study in Korean patients | Abstract |
| Kyung Hee Lee, MD, Min Kyoung Kim, MD, Myung Soo Hyun, MD, Jin Young Kim, MD, Keon Uk Park, MD, Hong Suk Song, MD, PhD, Sun Ah Lee, MD, Won Sik Lee, MD, Sung Hwa Bae, MD, Hun Mo Ryoo, MD, Yoon Young Cho, MD | ||
| Vol 10, No 6 (2014): November/December | Clinical interpretation of opioid tolerance versus opioid-induced hyperalgesia | Abstract |
| Lucy Chen, MD, Michael Sein, MD, Trang Vo, BA, Shihab Amhmed, MD, Yi Zhang, MD, Kristin St Hilaire, BA, PhD, Mary Houghton, BA, Jianren Mao, MD, PhD | ||
| Vol 19, No 2 (2023): March/April | Clinical practice patterns of opioid prescribing by physicians performing percutaneous spinal cord stimulation trials and implants | Abstract |
| Keisha Dodman, MD, Thomas T. Simopoulos, MD, Lynn Kohan, MD, Jamal Hasoon, MD, Jatinder Gill, MD | ||
| Vol 4, No 6 (2008): November/December | Clinical rationale for administering fentanyl to cancer pain patients: Two Delphi surveys of pain management experts in Denmark | Abstract |
| Ramune Jacobsen, MS, MPH, Claus Møldrup, PhD, Lona Christrup, PhD | ||
| Vol 13, No 2 (2017): March/April | Clinical relevance of the pharmacokinetic characteristics of an abuse-deterrent, extended-release, injection-molded morphine tablet | Abstract |
| Jeffrey M. Dayno, MD, Gwendolyn Niebler, DO, John Lawler, BS, Torben Elhauge, MSc, Karsten Lindhardt, MSc, PhD, DBE | ||
| Vol 18, No 3 (2022): May/June | Clinical role and safety of tapentadol in patients with cancer: A single-center experience | Abstract |
| Emi Kubo, MD, PhD, Hiroto Ishiki, MD, Kentaro Abe, MS, Sawako Kaku, MD, Sayuri Yokota, MD, Sayaka Arakawa, MD, PhD, Daisuke Kiuchi, MD, Koji Amano, MD, Eriko Satomi, MD | ||
| Vol 12, No 5 (2016): September/October | Clinically relevant concentrations of opioids for in vitro studies | Abstract |
| Jason W. Boland, FRCP, PhD, A. Graham Pockley, PhD | ||
| Vol 14, No 5 (2018): September/October | Clinician opioid prescribing practices and patient utilization of prescribed opioids in pediatrics | Abstract |
| Jeannie S. Huang, MD, MPH, Cynthia L. Kuelbs, MD | ||
| Vol 11, No 3 (2015): May/June | Communication about opioid versus nonopioid analgesics in the emergency department | Abstract |
| Danielle M. McCarthy, MD, MS, Kenzie A. Cameron, PhD, MPH, D. Mark Courtney, MD, MS, James G. Adams, MD, Kirsten G. Engel, MD | ||
| Vol 14, No 3 (2018): May/June | Communication between nurse care managers and patients who take opioids for chronic pain: Strategies for exploring aberrant behavior | Abstract |
| Jane M. Liebschutz, MD, MPH, Allison V. Lange, MD, Orlaith D. Heymann, MA, Karen E. Lasser, MD, MPH, Pamela Corey, MSN, EdD, RN, CHSE, Christopher W. Shanahan, MD, MPH, Hannah S. Kopinski, BA, Jawad M. Husain, MD, Phoebe A. Cushman, MD, MS, Victoria A. Parker, EdM, DBA | ||
| Vol 16, No 2 (2020): March/April | Comorbidities in an Australian sample of chronic and new opioid users | Abstract |
| Anna K. Moffat, PhD, Nicole L. Pratt, PhD, Lisa M. Kalisch Ellett, PhD, Emmae N. Ramsay, MSc, Elizabeth E. Roughead, PhD | ||
| Vol 13, No 4 (2017): July/August | Comparing methods of naloxone administration: A narrative review | Abstract |
| Shawn E. Fellows, PharmD, Alexander J. Coppola, BS, EMT-B, PharmD, Mona A. Gandhi, PharmD | ||
| Vol 18, No 6 (2022): November/December | Comparing the safety and efficacy of intravenous naloxone administration in opioid-naive and opioid-tolerant hospitalized oncology patients | Abstract |
| Stephanie Lee, PharmD, Vineet Tatla, PharmD, Sorin Buga, MD, Doreen Pon, PharmD, BCOP, BCPS | ||
| Vol 9, No 6 (2013): November/December | Comparison of 75 and 150 µg doses of intrathecal morphine for postoperative analgesia after transurethral resection of the prostate under spinal anesthesia | Abstract |
| Halime Özbek, MD, Mustafa N. Deniz, MD, Arzum Erakgun, MD, Elvan Erhan, MD | ||
| Vol 9, No 1 (2013): January/February | Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects | Abstract |
| Jatinder Mohan Chawla, MD, Hemraj Pal, MD, Rakesh Lal, MD, Raka Jain, PhD, Nina Schooler, PhD, Yatan Pal Singh Balhara, MD | ||
| Vol 18, No 1 (2022): January/February | Comparison of PACU length of stay and opioid requirements of patients maintained on buprenorphine or methadone for opioid use disorder | Abstract |
| Rebecca C. Dale, DO, Carol L. Metcalf, ARNP, Christina Bockman, PharmD, Dale J. Langford, PhD, Christine T. Fong, MS, Katherin A. Peperzak, MD | ||
| Vol 6, No 6 (2010): November/December | Comparison of postoperative analgesia with epidural butorphanol/bupivacaine versus fentanyl/bupivacaine following pediatric urological procedures | Abstract |
| Alexandra Szabova, MD, Senthilkumar Sadhasivam, MD, MPH, Yu Wang, MS, Todd G. Nick, PhD, Kenneth Goldschneider, MD | ||
| Vol 19, No 2 (2023): March/April | Comparison of the Centers for Disease Control (CDC) recommendations and the risk index for overdose or serious opioid-induced respiratory depression (RIOSORD) tool for guiding naloxone coprescribing | Abstract |
| Christopher M. Herndon, PharmD, Taylor R. Kirby, PharmD, Kelsey J. Madison, PharmD, Jessica L. Kerr, PharmD, CDCES | ||
| Vol 5, No 5 (2009): September/October | Comparison of the effect of adding remifentanil to patient-controlled tramadol or morphine for postoperative analgesia after major abdominal surgery | Abstract |
| Hakki Unlugenc, MD, Sibel Tetiker, MD, Selim Büyükkurt, MD, Tayfun Guler, MD, Geylan Isik, MD | ||
| Vol 6, No 2 (2010): March/April | Comparison of the postoperative analgesic efficacy of intravenous patient-controlled analgesia with tramadol to intravenous patient-controlled analgesia with opioids | Abstract |
| Jamie D. Murphy, MD, Dawn Yan, MD, Marie N. Hanna, MD, E. David Bravos, MD, Gillian R. Isaac, MD, PhD, Calvin A. Eng, MD, Christopher L. Wu, MD | ||
| Vol 1, No 4 (2005): September/October | Comparison of transdermal fentanyl with codeine/paracetamol, in combination with radiotherapy, for the management of metastatic bone pain | Abstract PDF |
| Kyriaki Mystakidou, MD, PhD, Emmanuela Katsouda, MD, PhD, Vassilios Kouloulias, MD, PhD, John Kouvaris, MD, PhD, Marinos Tsiatas, MD, Lambros Vlahos, MD, PhD | ||
| Vol 12, No 6 (2016): November/December | Complete Issue - November/December 2016 | Details |
| Various Authors | ||
| Vol 9, No 1 (2013): January/February | Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: Pooled analysis of randomized studies | Abstract |
| Sanjay Merchant, PhD, David Provenzano, MD, Samir Mody, PharmD, MBA, Kai Fai Ho, PhD, Mila Etropolski, MD | ||
| Vol 3, No 6 (2007): November/December | Comprehensibility and readability of patient self-administered Opioid Assessment Screening Tools | Abstract |
| Lorraine S. Wallace, PhD, Amy J. Keenum, PharmD, DO, Steven E. Roskos, MD | ||
| Vol 16, No 6 (2020): November/December | Concomitant use of benzodiazepines in chronic pain patients adherent to extended-release tapentadol or oxycodone treatment—A retrospective claims analysis | Abstract |
| Vladimir Zah, PhD, Martina Imro, MSc, Simona Tatovic, MSc, Michael DeGeorge, PharmD, Steven D. Passik, PhD, Djurdja Vukicevic, PhD(c) | ||
| Vol 1, No 2 (2005): May/June | Congratulations on the new journal | Abstract PDF |
| Mimi Mahon, PhD, FAAN | ||
| Vol 7, No 3 (2011): May/June | Considerations for the upcoming FDA REMS proposal | Abstract |
| John F. Peppin, DO, FACP, John J Coleman, PhD, Kenneth L. Kirsh, PhD | ||
| Vol 9, No 2 (2013): March/April | Consumer attitudes about opioid addiction treatment: A focus group study in New York City | Abstract |
| Nancy L. Sohler, PhD, MPH, Linda Weiss, PhD, James E. Egan, MPH, Carolina M. López, BS, Jamie Favaro, LMSW, Robert Cordero, MSW, Chinazo O. Cunningham, MD, MS | ||
| Vol 8, No 2 (2012): March/April | Continuous hydromorphone for pain and sedation in mechanically ventilated infants and children | Abstract |
| Pamela D. Reiter, PharmD, Jennifer Ng, PharmD, Emily L. Dobyns, MD | ||
| Vol 12, No 5 (2016): September/October | Coprescribing naloxone for patients on chronic opioid therapy: Lessons learned from a patient-safety initiative in primary care training sites | Abstract |
| William Delaney, MD, Jessica Huff, MPH, MS, Sandra Mini, MD, Aiswarya Thomas, MD, Ralph Tremaglio, MD | ||
| Vol 14, No 1 (2018): January/February | Correlates of opiate misuse based on aberrant urine drug tests for patients on chronic opiate therapy in a safety-net, academic primary care clinic | Abstract |
| Smita Bakhai, MD, MPH, FACP, Bright Thilagar, MD, Jessica L. Reynolds, PhD, Kenneth E. Leonard, PhD | ||
| Vol 6, No 2 (2010): March/April | Correlation between myoclonus and the 3-glucuronide metabolites in patients treated with morphine or hydromorphone: A pilot study | Abstract |
| Shawn McCann, MD, Tony L. Yaksh, PhD, Charles F. von Gunten, MD, PhD | ||
| Vol 13, No 3 (2017): May/June | Cost of opioid-treated chronic low back pain: Findings from a pilot randomized controlled trial of mindfulness meditation-based intervention | Abstract |
| Aleksandra E. Zgierska, MD, PhD, James Ircink, BBA, Cindy A. Burzinski, MS, Marlon P. Mundt, PhD | ||
| Vol 1, No 3 (2005): July/August | Cotton candy | Abstract PDF |
| Robert E. Enck, MD, Editor-in-Chief | ||
| Vol 7, No 1 (2011): January/February | Course of weight change during naltrexone versus methadone maintenance for opioid-dependent patients | Abstract |
| David J. Mysels, MD, MBA, Suzanne K. Vosburg, PhD, Ileana Benga, MD, Frances R. Levin, MD, Maria A. Sullivan, MD, PhD | ||
| Vol 6, No 6 (2010): November/December | Current concepts in the management of opioid-induced constipation | Abstract |
| John Brandon Walters, MD, Marcos Montagnini, MD, FACP | ||
| Vol 7, No 3 (2011): May/June | Current concepts in the management of opioid-induced constipation: A perfect review with an imperfect concept | Abstract |
| Xiulu Ruan, MD, Marcos Montagnini, MD, FACP, Brandon JB Walters, MD | ||
| Vol 15, No 5 (2019): September/October | Current practices in naloxone prescribing upon hospital discharge | Abstract |
| Michelle Punzal, MD, Patricia Santos, MD, MBA, Xiaoshu Li, PhD, Douglas R. Oyler, PharmD, Alan M. Hall, MD | ||
| Vol 7, No 3 (2011): May/June | Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain | Abstract |
| Lynn Webster, MD, Barbara St. Marie, NP, Bill McCarberg, MD, Steven D. Passik, PhD, Sunil J. Panchal, MD, Eric Voth, MD | ||
| Vol 11, No 3 (2015): May/June | Daily home opioid use in adults with sickle cell disease: The PiSCES project | Abstract |
| Wally R. Smith, MD, Donna K. McClish, PhD, Bassam A. Dahman, PhD, James L. Levenson, MD, Imoigele P. Aisiku, MD, MSCR, Vanessa de A. Citero, MD, Viktor E. Bovbjerg, PhD, MPH, John D. Roberts, MD, Lynne T. Penberthy, MD, MPH, Susan D. Roseff, MD | ||
| 1 - 250 of 1048 Items | 1 2 3 4 5 > >> | |